Tarus Therapeutics

New York, United States Founded: 2019 • Age: 7 yrs Acquired By Portage Biotech
Cancer therapeutics targeting the adenosine pathway are developed.

About Tarus Therapeutics

Tarus Therapeutics is a Healthcare company based in New York (United States) founded in 2019 by Donald R Dye and Peter Molloy, and was acquired by Portage Biotech in July 2022. Cancer therapeutics targeting the adenosine pathway are developed. The company was acqui-hired. Tarus Therapeutics offers products and services including iNKT Platform, Adenosine Platform, and Other Programs. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Portage Biotech Inc.

Company details

Tarus Therapeutics was founded in 2019 in New York, United States. Therapeutics for cancer treatment are developed by the company within the biotechnology sector. Lead candidates are focused on the immunosuppressive adenosine pathway in the tumor microenvironment. These candidates are aimed at addressing resistant cancers through operations centered on drug development. The companys activities are based in the United States.

  • Headquarters New York, United States
  • Founders Donald R Dye, Peter Molloy
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website tarustx.com
  • Social LinkedIn
  • Acquired by Portage Biotech (Jul 2022)
  • Legal Name Portage Biotech Inc.
Operational Areas
Key Metrics

Products & Services of Tarus Therapeutics

Tarus Therapeutics offers a comprehensive portfolio of products and services, including iNKT Platform, Adenosine Platform, and Other Programs.

iNKT Platform
Immuno-Oncology Therapy

Develops therapies targeting cancer resistance pathways

Adenosine Platform
Immuno-Oncology Therapy

Focuses on immuno-oncology drug development for cancer

Other Programs
Drug Development

Advances additional novel assets in oncology research

Investors in Tarus Therapeutics

Tarus Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Portage Biotech.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Therapeutics based on Cell Permeable Peptide Platform
2013portagebiotech.comTortola, United Kingdom
Premium access

Investor details for Tarus Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Tarus Therapeutics

2 people are tracked at Tarus Therapeutics (2 in leadership).

NameRoleGroup
Donald R Dye
Co-FounderLeadership
Peter Molloy
Co-FounderLeadership
Premium access

Complete people profiles for Tarus Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Tarus Therapeutics

2 dated milestones of Tarus Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Tarus Therapeutics is founded.
  2. Exit Acquired by Portage Biotech.

Top companies in Oncology

3 companies that operate in the same segment as Tarus Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tarus Therapeutics

Premium access

Complete news archive for Tarus Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tarus Therapeutics

Tarus Therapeutics was founded in 2019.

Tarus Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.

Tarus Therapeutics was founded in 2019 in New York, United States. Therapeutics for cancer treatment are developed by the company within the biotechnology sector. Lead candidates are focused on the immunosuppressive adenosine pathway in the tumor microenvironment. These candidates are aimed at addressing resistant cancers through operations centered on drug development. The companys activities are based in the United States.

Tarus Therapeutics offers iNKT Platform, Adenosine Platform, and Other Programs.

Tarus Therapeutics has 1 investor. Key investors include Portage Biotech.

Tarus Therapeutics operates through Portage Biotech Inc..

Yes. Tarus Therapeutics was acquired by Portage Biotech in July 2022.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available